Travere Therapeutics gains FDA approval for sparsentan in FSGS
Pharmaceutical Business Review
The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition.
pharminent
April 14, 2026 (Last updated: April 14, 2026)
Pharmaceutical Business Review
The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition.
